Proactiveinvestors United Kingdom Abcam https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Abcam RSS feed en Thu, 18 Jul 2019 23:12:38 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Acquisition of Cell Lines and Lysates Portfolio ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190716070008_14150328/ Tue, 16 Jul 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190716070008_14150328/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190701093846_14130958/ Mon, 01 Jul 2019 09:38:46 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190701093846_14130958/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190603104507_14096093/ Mon, 03 Jun 2019 10:45:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190603104507_14096093/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190502125339_14061199/ Thu, 02 May 2019 12:53:39 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190502125339_14061199/ <![CDATA[RNS press release - Appointment of Joint Broker ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190501070003_14058334/ Wed, 01 May 2019 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190501070003_14058334/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190402131318_14025806/ Tue, 02 Apr 2019 13:13:18 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190402131318_14025806/ <![CDATA[RNS press release - Company Secretary Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190329070009_14020470/ Fri, 29 Mar 2019 07:00:09 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190329070009_14020470/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190312070022_13998159/ Tue, 12 Mar 2019 07:00:22 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190312070022_13998159/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190308085707_13995433/ Fri, 08 Mar 2019 08:57:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190308085707_13995433/ <![CDATA[RNS press release - Interim results for six months ended 31 Dec 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190304070007_13988227/ Mon, 04 Mar 2019 07:00:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190304070007_13988227/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190301102904_13987213/ Fri, 01 Mar 2019 10:29:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190301102904_13987213/ <![CDATA[RNS press release - Change of Registered Office ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190225173952_13981027/ Mon, 25 Feb 2019 17:39:52 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190225173952_13981027/ <![CDATA[RNS press release - Block listing Interim Review ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190218130131_13973048/ Mon, 18 Feb 2019 13:01:31 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190218130131_13973048/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190205113432_13958867/ Tue, 05 Feb 2019 11:34:32 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190205113432_13958867/ <![CDATA[RNS press release - Acquisition of Calico Biolabs ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190128070007_13947971/ Mon, 28 Jan 2019 07:00:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190128070007_13947971/ <![CDATA[News - Abcam on track to meet its full-year target after posting top line growth of 11% in the first half ]]> https://www.proactiveinvestors.co.uk/companies/news/212120/abcam-on-track-to-meet-its-full-year-target-after-posting-top-line-growth-of-11-in-the-first-half-212120.html Abcam PLC (LON:ABC), which supplies antibodies for research, said it is on track to meet its full-year 2019 financial targets after posting double-digit first-half growth.

In an update, it said revenues grew by 11% on a reported basis or 10% at constant at currencies.

READ: Abcam shares tumble as outlook misses expectations despite double-digit earnings growth in full year

Abcam said it continued to gain market share in the global research market, particularly in the areas of recombinant antibodies and immunoassays. Expansion in China has also helped underpin its success.

"Global demand is strong for precision life science tools and Abcam has once again gained market share in these growing markets.  Our business is on track to achieve double-digit growth for the year,” said chief executive Alan Hirzel.

"During the half, we have continued to focus on improving our service for customers.

“We have further developed our product portfolio and we have continued to enhance our organisational capabilities to support our ambition of becoming the most influential company for life scientists, supporting research, diagnostic and therapeutic discovery."

]]>
Tue, 08 Jan 2019 08:02:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212120/abcam-on-track-to-meet-its-full-year-target-after-posting-top-line-growth-of-11-in-the-first-half-212120.html
<![CDATA[RNS press release - Half Year Trading Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190108070002_13926591/ Tue, 08 Jan 2019 07:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190108070002_13926591/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190103134553_13923113/ Thu, 03 Jan 2019 13:45:53 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190103134553_13923113/ <![CDATA[RNS press release - Abcam to present at J.P. Morgan Conference ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190103070011_13922063/ Thu, 03 Jan 2019 07:00:11 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20190103070011_13922063/ <![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181213100613_13902597/ Thu, 13 Dec 2018 10:06:13 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181213100613_13902597/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181206130637_13894443/ Thu, 06 Dec 2018 13:06:37 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181206130637_13894443/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181203160206_13889593/ Mon, 03 Dec 2018 16:02:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181203160206_13889593/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181203122145_13889198/ Mon, 03 Dec 2018 12:21:45 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181203122145_13889198/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181112135919_13863721/ Mon, 12 Nov 2018 13:59:19 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181112135919_13863721/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181108093249_13859943/ Thu, 08 Nov 2018 09:32:49 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181108093249_13859943/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181106174713_13857402/ Tue, 06 Nov 2018 17:47:13 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181106174713_13857402/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181102085128_13852962/ Fri, 02 Nov 2018 08:51:28 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181102085128_13852962/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181101132217_13851781/ Thu, 01 Nov 2018 13:22:17 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181101132217_13851781/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181029085744_13845696/ Mon, 29 Oct 2018 08:57:44 +0000 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181029085744_13845696/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181010104622_13823347/ Wed, 10 Oct 2018 10:46:22 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181010104622_13823347/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181009085958_13821348/ Tue, 09 Oct 2018 08:59:58 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181009085958_13821348/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181002125401_13813371/ Tue, 02 Oct 2018 12:54:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181002125401_13813371/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181002125116_13813369/ Tue, 02 Oct 2018 12:51:16 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181002125116_13813369/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181001174136_13812045/ Mon, 01 Oct 2018 17:41:36 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20181001174136_13812045/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180928101102_13808750/ Fri, 28 Sep 2018 10:11:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180928101102_13808750/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180924144228_13802330/ Mon, 24 Sep 2018 14:42:28 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180924144228_13802330/ <![CDATA[RNS press release - Annual Financial Report ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180921125617_13800437/ Fri, 21 Sep 2018 12:56:17 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180921125617_13800437/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180914094635_13791298/ Fri, 14 Sep 2018 09:46:35 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180914094635_13791298/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180913133428_13790053/ Thu, 13 Sep 2018 13:34:28 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180913133428_13790053/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180913133302_13790051/ Thu, 13 Sep 2018 13:33:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180913133302_13790051/ <![CDATA[RNS press release - Dividend Payment Date ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180911103005_13786376/ Tue, 11 Sep 2018 10:30:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180911103005_13786376/ <![CDATA[RNS press release - Preliminary Results 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180910112200_13784867/ Mon, 10 Sep 2018 11:22:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180910112200_13784867/ <![CDATA[News - Abcam shares tumble as outlook misses expectations despite double-digit earnings growth in full year ]]> https://www.proactiveinvestors.co.uk/companies/news/204509/abcam-shares-tumble-as-outlook-misses-expectations-despite-double-digit-earnings-growth-in-full-year-204509.html Abcam PLC (LON:ABC) saw its shares take a tumble in early trading Monday despite double-digit growth in its underlying earnings (EBITDA) for the full year after its estimates for the new financial year missed expectations.

The AIM 100 supplier of research tools to the life sciences industry reported adjusted EBITDA for the year of £88.3mln, up 20.5% on the previous year, while revenues climbed 7.4% to £233.2mln (or 10.7% on a constant currency basis).

READ: Abcam forecasts double-digit revenue growth for full-year as it sees product growth across the board

The company also upped its final dividend for the year to 8.58p from 7.36p the year before, increasing its total dividend 17.9% to 12p per share.

The double-digit growth and dividend hike weren’t enough to placate shareholders though, with the stock tumbling 23.3% to 1,137p after Abcam forecast that its adjusted EBITDA margin for the new financial year would be around 36% because of increased investment in its strategic initiatives.

Analysts at City broker Peel Hunt said that margin forecast had come in “well below” their estimates of 39% for the new financial year, while also being less than the margin reported in the results, which grew to 37.9% from 33.8% the previous year.

The broker added that the full year adjusted EBITDA of £88.3mln had come in below analyst estimates of £90.4mln for the period and expected a “significant pull-back” in the share price in response.

 

]]>
Mon, 10 Sep 2018 08:43:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204509/abcam-shares-tumble-as-outlook-misses-expectations-despite-double-digit-earnings-growth-in-full-year-204509.html
<![CDATA[RNS press release - Preliminary Results 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180910070005_13783836/ Mon, 10 Sep 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180910070005_13783836/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180904075701_13777867/ Tue, 04 Sep 2018 07:57:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180904075701_13777867/ <![CDATA[RNS press release - Block listing Interim Review ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180814085430_13754485/ Tue, 14 Aug 2018 08:54:30 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180814085430_13754485/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180802070834_13740715/ Thu, 02 Aug 2018 07:08:34 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180802070834_13740715/ <![CDATA[News - Abcam back on the buy list at Berenberg ]]> https://www.proactiveinvestors.co.uk/companies/news/201920/abcam-back-on-the-buy-list-at-berenberg-201920.html Having downgraded Abcam PLC (LON:ABC) three months ago, Berenberg has had a change of heart over the antibodies supplier.

The German bank’s explanation for the April downgrade was that it felt it was missing some insight into the company that could persuade it to take a more bullish view.

It has now found that insight in the form of the ‘Abcam Inside’ initiative.

READ: Abcam forecasts double-digit revenue growth for full-year as it sees product growth across the board​

“‘Abcam Inside’ is the name for Abcam’s work with diagnostic and therapeutic companies, where it provides them with commercial rights to specific antibodies in return for a small upfront fee and low to mid-single-digit royalties on sales,” Berenberg explained.

Berenberg’s conversations with in-vitro diagnostic (IVD) developers and Abcam’s competitors has helped it make a better estimate of royalty rates, success rates and the commercial potential of diagnostic tests, based on which it ascribes a value of 500p per share to the ‘Abcam Inside’ business alone.

That forms 30% of the bank’s 1,640p price target for Abcam, although Berenberg has only baked in a 250p per share ‘Abcam Inside’ element to its price target, with the rest coming from the therapeutics business.

“We have taken the opportunity to revisit academic citation trends, analysed from the proprietary CiteAb database, and these show that Abcam has accelerated its overall market share gains,” Berenberg revealed.

“China, where Abcam is stretching its leadership position, continues to be a key driver of growth, and the company is also gaining share from the one main competitor in rabbit monoclonal antibodies, the fastest growth category in research antibodies overall. Abcam’s recent trading statement confirms that it is growing around twice the market rate,” it added.

Meanwhile, barriers to entry in research antibodies remain very high, while a proven antibody “essentially becomes an annuity stream”, Bergenberg asserted, as it moved its rating back to ‘buy’.

 

The difference between m6A and 5fC? Find the answer and more in our awesome RNA and DNA mods guide! https://t.co/XoR7rBGeEu #epigenetics pic.twitter.com/fm0y0m3xUt

— Abcam (@abcam) July 30, 2018

Abcam shares were up 4.9% at 1,422p.

]]>
Tue, 31 Jul 2018 12:08:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/201920/abcam-back-on-the-buy-list-at-berenberg-201920.html
<![CDATA[News - Abcam forecasts double digit revenue growth for full-year as it sees product growth across the board ]]> https://www.proactiveinvestors.co.uk/companies/news/200682/abcam-forecasts-double-digit-revenue-growth-for-full-year-as-it-sees-product-growth-across-the-board-200682.html Abcam PLC (LON:ABC) said it expects double-digit growth in its full-year results following strong income growth across all of its product categories.

The AIM-listed antibody supplier said it expects revenue for the full year to grow by 10.7% in constant currency, with catalogue growth of “over” 10% underpinning the rise after all product categories continued to grow ahead of its market.

READ: Abcam raises revenue guidance after Roche deal

The firm added that revenue from custom products and licensing, which accounted for around 7% of total revenue, also grew by 18% during the year.

Abcam also said it expected margins to be in line with the previous year's figure of 70.1%, while margins for adjusted earnings before interest, taxes, depreciation and amortisation were forecast to be in line with expectations.

In a note to clients, analysts at City broker Numis upped their target price for the firm to 1,380p from 1,316p, citing that the strong growth forecasts could “indicate the emergence of a new fourth double-digit growth engine in the business”.

In lunchtime trading Thursday, Abcam shares were down 4.8% at 1,322p.

]]>
Thu, 12 Jul 2018 11:59:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/200682/abcam-forecasts-double-digit-revenue-growth-for-full-year-as-it-sees-product-growth-across-the-board-200682.html
<![CDATA[RNS press release - Full Year Trading Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180712070005_13714747/ Thu, 12 Jul 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/9/LSE20180712070005_13714747/